164 related articles for article (PubMed ID: 15550484)
1. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.
Spina M; Jaeger U; Sparano JA; Talamini R; Simonelli C; Michieli M; Rossi G; Nigra E; Berretta M; Cattaneo C; Rieger AC; Vaccher E; Tirelli U
Blood; 2005 Mar; 105(5):1891-7. PubMed ID: 15550484
[TBL] [Abstract][Full Text] [Related]
2. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
Tirelli U; Spina M; Jaeger U; Nigra E; Blanc PL; Liberati AM; Benci A; Sparano JA
Recent Results Cancer Res; 2002; 159():149-53. PubMed ID: 11785839
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
[TBL] [Abstract][Full Text] [Related]
4. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493).
Sparano JA; Weller E; Nazeer T; Habermann T; Traynor AE; Manalo J; Cassileth P
Blood; 2002 Sep; 100(5):1634-40. PubMed ID: 12176882
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Castillo JJ; Echenique IA
Am J Hematol; 2012 Mar; 87(3):330-3. PubMed ID: 22308010
[TBL] [Abstract][Full Text] [Related]
7. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Barta SK; Xue X; Wang D; Tamari R; Lee JY; Mounier N; Kaplan LD; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Wilson WH; Wyen C; Oriol A; Navarro JT; Dunleavy K; Little RF; Ratner L; Garcia O; Morgades M; Remick SC; Noy A; Sparano JA
Blood; 2013 Nov; 122(19):3251-62. PubMed ID: 24014242
[TBL] [Abstract][Full Text] [Related]
8. HIV-associated lymphoma: promising new results, but with toxicity.
Straus DJ
Blood; 2005 Mar; 105(5):1842. PubMed ID: 15747398
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
10. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.
Sparano JA; Wiernik PH; Hu X; Sarta C; Henry DH; Ratech H
Med Oncol; 1998 Apr; 15(1):50-7. PubMed ID: 9643531
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
Levine AM; Noy A; Lee JY; Tam W; Ramos JC; Henry DH; Parekh S; Reid EG; Mitsuyasu R; Cooley T; Dezube BJ; Ratner L; Cesarman E; Tulpule A
J Clin Oncol; 2013 Jan; 31(1):58-64. PubMed ID: 23169503
[TBL] [Abstract][Full Text] [Related]
14. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
Sparano JA; Wiernik PH; Leaf A; Dutcher JP
J Clin Oncol; 1993 Jun; 11(6):1071-9. PubMed ID: 8501493
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
Sparano JA; Lee S; Chen MG; Nazeer T; Einzig A; Ambinder RF; Henry DH; Manalo J; Li T; Von Roenn JH
J Clin Oncol; 2004 Apr; 22(8):1491-500. PubMed ID: 15084622
[TBL] [Abstract][Full Text] [Related]
17. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
[TBL] [Abstract][Full Text] [Related]
20. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen.
Sparano JA; Wiernik PH; Strack M; Leaf A; Becker N; Valentine ES
Blood; 1993 May; 81(10):2810-5. PubMed ID: 8490187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
